Pfizer
Pfizer is a research-based biopharmaceutical company, developing and manufacturing human and veterinary medicines, as well as consumer healthcare products. The Company applies science and its global resources to improve health and well-being at every stage of life. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products, and many consumer health care products. The Company operates in two business segments: biopharmaceutical and diversified. Biopharmaceutical segment includes the primary and specialty care, established products, emerging markets and oncology customer-focused units. Diversified segment offers animal health products that prevent and treat diseases in livestock and companion animals, and consumer healthcare products. Pfizer develops and produces medicines and vaccines for a wide range of conditions including in the areas of immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain.
| Type | Public |
| HQ | New York, US |
| Founded | 1849 |
| Size (employees) | 90,200 (est)-6% |
| Website | pfizer.com |
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Pfizer
Ian C. Read
Albert Bourla
Frank D'Amelio
Mikael Dolsten
Michael Goettler
Angela Hwang
Pfizer Office Locations
Pfizer Financials and Metrics
Pfizer Revenue
| USD | |
|---|---|
Revenue (Q2, 2019) | 26.4b |
Gross profit (Q2, 2019) | 20.9b |
Gross profit margin (Q2, 2019), % | 79.2% |
Net income (Q2, 2019) | 7.4b |
Market capitalization (15-Oct-2018) | 252.8b |
Closing stock price (15-Oct-2018) | 43.1 |
Cash (1-Jul-2018) | 2.7b |
EV | 279.0b |
- Source: SEC Filings
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 51.6b | 49.6b | 48.9b | 52.8b |
Revenue growth, % | (4%) | (2%) | 8% | |
Cost of goods sold | 9.6b | 9.6b | 9.6b | 12.3b |
Gross profit | 42.0b | 40.0b | 39.2b | 40.5b |
- Source: SEC Filings
| usd | Y, 2011 | Y, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|---|---|
Cash | 3.2b | 10.1b | 2.2b | 3.3b | 3.6b | |
Inventories | 6.2b | 5.7b | ||||
Current Assets | 56.2b | 57.7b | 43.8b | 38.9b | ||
PP&E | 12.4b | 11.8b |
| USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q3, 2016 | Q1, 2016 | Q2, 2016 | Q1, 2017 | Q2, 2017 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 2.1b | 2.9b | 3.4b | 2.4b | 3.6b | 3.7b | 3.1b | 2.3b | 2.7b | |||||
Inventories | 6.5b | 6.1b | 6.2b | 6.4b | 5.8b | 5.8b | 7.6b | 7.6b | 8.1b | 8.1b | ||||
Current Assets | 59.5b | 57.8b | 58.3b | 57.0b | 49.4b | 51.7b | 45.0b | 38.5b | 41.3b | 43.8b | 35.9b | 36.4b | 34.8b | 37.3b |
PP&E | 12.4b | 12.3b | 12.2b | 12.0b | 11.5b | 11.4b | 13.7b |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 22.1b | 9.2b | ||
Inventories | (538.0m) | 175.0m | (199.0m) | 365.0m |
Accounts Payable | 382.0m | 297.0m | 254.0m | 871.0m |
Cash From Operating Activities | 17.8b | 16.9b | 14.5b | 15.9b |
| USD | Y, 2018 |
|---|---|
EV/CFO | 47.9 x |
Financial Leverage | 2.4 x |
Pfizer Acquisitions / Subsidiaries
| Acquired Company | Date | Deal Size |
|---|---|---|
| Medivation | August 22, 2016 | $14 b |
| Anacor Pharmaceuticals | June 24, 2016 | $5.20 b |
| Allergan | November 23, 2015 | $160 b |
Pfizer Revenue Breakdown
Pfizer revenue breakdown by business segment: 18.6% from GIP, 17.0% from VOC, 35.6% from Innovative Products and 28.7% from Established Products GEP
Pfizer Online and Social Media Presence
14.65k Twitter followers
Pfizer has 14.65k Twitter Followers. The number of followers has increased 1.3% month over month and increased 2.5% quarter over quarter
346.18k Facebook likes
Pfizer has 346.18k Facebook Likes. The number of likes has increased 0.3% month over month and increased 1% quarter over quarter